{
  "study_id": "NCT01607957",
  "study_title": "Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer",
  "table_name": "Table 1",
  "table_title": "Baseline Characteristics of the Intention-to-Treat Population.",
  "footnotes": [
    "Baseline demographic and disease characteristics were well balanced between the two study groups. EGFR denotes epidermal growth factor receptor.",
    "Race was self-reported.",
    "Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale of 0 to 5, with 0 indicating no symptoms, 1 indicating mild symptoms, and higher numbers indicating increasing degrees of disability."
  ],
  "groups": [
    {
      "name": "TAS-102",
      "n": 534,
      "type": "Intervention"
    },
    {
      "name": "Placebo",
      "n": 266,
      "type": "Control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age — yr",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Age — yr"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Age — yr"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age, Median",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "numeric_median_iqr",
          "median": 63.0,
          "raw_string": "63"
        },
        {
          "group_name": "Placebo",
          "data_type": "numeric_median_iqr",
          "median": 63.0,
          "raw_string": "63"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age, Range",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "numeric_mean_range",
          "range_min": 27.0,
          "range_max": 82.0,
          "raw_string": "27-82"
        },
        {
          "group_name": "Placebo",
          "data_type": "numeric_mean_range",
          "range_min": 27.0,
          "range_max": 82.0,
          "raw_string": "27-82"
        }
      ]
    },
    {
      "original_label": "Sex — no. (%)",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Sex — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Sex — no. (%)"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex, Male",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 326.0,
          "percentage": 61.0,
          "raw_string": "326 (61)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 165.0,
          "percentage": 62.0,
          "raw_string": "165 (62)"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex, Female",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 208.0,
          "percentage": 39.0,
          "raw_string": "208 (39)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 38.0,
          "raw_string": "101 (38)"
        }
      ]
    },
    {
      "original_label": "Race — no. (%)",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Race — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Race — no. (%)"
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race, White",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 306.0,
          "percentage": 57.0,
          "raw_string": "306 (57)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 155.0,
          "percentage": 58.0,
          "raw_string": "155 (58)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Race, Asian",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 184.0,
          "percentage": 34.0,
          "raw_string": "184 (34)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 94.0,
          "percentage": 35.0,
          "raw_string": "94 (35)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Race, Black",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.0,
          "raw_string": "4 (<1)",
          "notes": "Percentage is <1"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 2.0,
          "raw_string": "5 (2)"
        }
      ]
    },
    {
      "original_label": "Region — no. (%)",
      "standardized_name": "Geographic Region",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Region — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Region — no. (%)"
        }
      ]
    },
    {
      "original_label": "Japan",
      "standardized_name": "Geographic Region, Japan",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 178.0,
          "percentage": 33.0,
          "raw_string": "178 (33)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 88.0,
          "percentage": 33.0,
          "raw_string": "88 (33)"
        }
      ]
    },
    {
      "original_label": "United States, Europe, and Australia",
      "standardized_name": "Geographic Region, United States, Europe, and Australia",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 356.0,
          "percentage": 67.0,
          "raw_string": "356 (67)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 178.0,
          "percentage": 67.0,
          "raw_string": "178 (67)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status — no. (%)",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "ECOG performance status — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "ECOG performance status — no. (%)"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status, 0",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 301.0,
          "percentage": 56.0,
          "raw_string": "301 (56)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 147.0,
          "percentage": 55.0,
          "raw_string": "147 (55)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status, 1",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 233.0,
          "percentage": 44.0,
          "raw_string": "233 (44)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 119.0,
          "percentage": 45.0,
          "raw_string": "119 (45)"
        }
      ]
    },
    {
      "original_label": "Primary site of disease — no. (%)",
      "standardized_name": "Primary Site of Disease",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Primary site of disease — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Primary site of disease — no. (%)"
        }
      ]
    },
    {
      "original_label": "Colon",
      "standardized_name": "Primary Site of Disease, Colon",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary Site of Disease",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 338.0,
          "percentage": 63.0,
          "raw_string": "338 (63)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 161.0,
          "percentage": 61.0,
          "raw_string": "161 (61)"
        }
      ]
    },
    {
      "original_label": "Rectum",
      "standardized_name": "Primary Site of Disease, Rectum",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary Site of Disease",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 196.0,
          "percentage": 37.0,
          "raw_string": "196 (37)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 39.0,
          "raw_string": "105 (39)"
        }
      ]
    },
    {
      "original_label": "KRAS mutation — no. (%)",
      "standardized_name": "KRAS Mutation Status",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "KRAS mutation — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "KRAS mutation — no. (%)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "KRAS Mutation Status, No (Wild-type)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "KRAS Mutation Status",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 262.0,
          "percentage": 49.0,
          "raw_string": "262 (49)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 131.0,
          "percentage": 49.0,
          "raw_string": "131 (49)"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "KRAS Mutation Status, Yes (Mutant)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "KRAS Mutation Status",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 272.0,
          "percentage": 51.0,
          "raw_string": "272 (51)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 135.0,
          "percentage": 51.0,
          "raw_string": "135 (51)"
        }
      ]
    },
    {
      "original_label": "Time from diagnosis of metastases — no. (%)",
      "standardized_name": "Time from Diagnosis of Metastases",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Time from diagnosis of metastases — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Time from diagnosis of metastases — no. (%)"
        }
      ]
    },
    {
      "original_label": "<18 mo",
      "standardized_name": "Time from Diagnosis of Metastases, <18 months",
      "unit": "months",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from Diagnosis of Metastases",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 21.0,
          "raw_string": "111 (21)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 55.0,
          "percentage": 21.0,
          "raw_string": "55 (21)"
        }
      ]
    },
    {
      "original_label": "≥18 mo",
      "standardized_name": "Time from Diagnosis of Metastases, ≥18 months",
      "unit": "months",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from Diagnosis of Metastases",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 423.0,
          "percentage": 79.0,
          "raw_string": "423 (79)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 211.0,
          "percentage": 79.0,
          "raw_string": "211 (79)"
        }
      ]
    },
    {
      "original_label": "Number of prior regimens — no. (%)",
      "standardized_name": "Number of Prior Regimens",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Number of prior regimens — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Number of prior regimens — no. (%)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Prior Regimens, 2",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Regimens",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 95.0,
          "percentage": 18.0,
          "raw_string": "95 (18)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 17.0,
          "raw_string": "45 (17)"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "Number of Prior Regimens, 3",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Regimens",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 119.0,
          "percentage": 22.0,
          "raw_string": "119 (22)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 20.0,
          "raw_string": "54 (20)"
        }
      ]
    },
    {
      "original_label": "≥4",
      "standardized_name": "Number of Prior Regimens, ≥4",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Regimens",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 320.0,
          "percentage": 60.0,
          "raw_string": "320 (60)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 63.0,
          "raw_string": "167 (63)"
        }
      ]
    },
    {
      "original_label": "Prior systemic anticancer agents — no. (%)",
      "standardized_name": "Prior Systemic Anticancer Agents",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Prior systemic anticancer agents — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Prior systemic anticancer agents — no. (%)"
        }
      ]
    },
    {
      "original_label": "Fluoropyrimidine",
      "standardized_name": "Prior Systemic Anticancer Agents, Fluoropyrimidine",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 534.0,
          "percentage": 100.0,
          "raw_string": "534 (100)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 100.0,
          "raw_string": "266 (100)"
        }
      ]
    },
    {
      "original_label": "Irinotecan",
      "standardized_name": "Prior Systemic Anticancer Agents, Irinotecan",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 534.0,
          "percentage": 100.0,
          "raw_string": "534 (100)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 100.0,
          "raw_string": "266 (100)"
        }
      ]
    },
    {
      "original_label": "Oxaliplatin",
      "standardized_name": "Prior Systemic Anticancer Agents, Oxaliplatin",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 534.0,
          "percentage": 100.0,
          "raw_string": "534 (100)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 100.0,
          "raw_string": "266 (100)"
        }
      ]
    },
    {
      "original_label": "Bevacizumab",
      "standardized_name": "Prior Systemic Anticancer Agents, Bevacizumab",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 534.0,
          "percentage": 100.0,
          "raw_string": "534 (100)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 265.0,
          "percentage": 99.0,
          "raw_string": "265 (>99)",
          "notes": "Percentage is >99"
        }
      ]
    },
    {
      "original_label": "Anti-EGFR monoclonal antibody",
      "standardized_name": "Prior Systemic Anticancer Agents, Anti-EGFR monoclonal antibody",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 278.0,
          "percentage": 52.0,
          "raw_string": "278 (52)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 144.0,
          "percentage": 54.0,
          "raw_string": "144 (54)"
        }
      ]
    },
    {
      "original_label": "Regorafenib",
      "standardized_name": "Prior Systemic Anticancer Agents, Regorafenib",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Systemic Anticancer Agents",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 91.0,
          "percentage": 17.0,
          "raw_string": "91 (17)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 20.0,
          "raw_string": "53 (20)"
        }
      ]
    },
    {
      "original_label": "Refractory to fluoropyrimidine — no. (%)",
      "standardized_name": "Refractory to Fluoropyrimidine",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "header",
          "raw_string": "Refractory to fluoropyrimidine — no. (%)"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Refractory to fluoropyrimidine — no. (%)"
        }
      ]
    },
    {
      "original_label": "As part of any prior treatment regimen",
      "standardized_name": "Refractory to Fluoropyrimidine, As part of any prior treatment regimen",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Fluoropyrimidine",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 524.0,
          "percentage": 98.0,
          "raw_string": "524 (98)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 265.0,
          "percentage": 99.0,
          "raw_string": "265 (>99)",
          "notes": "Percentage is >99"
        }
      ]
    },
    {
      "original_label": "At time of last exposure",
      "standardized_name": "Refractory to Fluoropyrimidine, At time of last exposure",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Fluoropyrimidine",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 497.0,
          "percentage": 93.0,
          "raw_string": "497 (93)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 240.0,
          "percentage": 90.0,
          "raw_string": "240 (90)"
        }
      ]
    },
    {
      "original_label": "As part of last regimen before study entry",
      "standardized_name": "Refractory to Fluoropyrimidine, As part of last regimen before study entry",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Fluoropyrimidine",
      "group_data": [
        {
          "group_name": "TAS-102",
          "data_type": "categorical_count_percentage",
          "count": 311.0,
          "percentage": 58.0,
          "raw_string": "311 (58)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 144.0,
          "percentage": 54.0,
          "raw_string": "144 (54)"
        }
      ]
    }
  ]
}